Multiple sclerosis Archives

In Depth 23 Apr 2025

The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in on FDA approval.

April 23, 2025 - 9 minutesmins - By Willow Shah-Neville

Best in Biotech 24 Oct 2024

Six biotech companies advancing multiple sclerosis therapies

Take a look at six multiple sclerosis companies trying to make a difference to patients by advancing new treatments for the CNS disease.

October 24, 2024 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 15 Aug 2024

10 neuroscience biotech companies you should know about

Learn more about nine of the top neuroscience biotech companies looking to develop treatments for difficult-to-treat neurological conditions.

August 15, 2024 - 12 minutesmins - By Willow Shah-Neville

In Depth 27 Mar 2024

Are new treatments for multiple sclerosis on the horizon?

As the wait for new multiple sclerosis treatments continue, here are some ongoing clinical trials that hold promise.

March 27, 2024 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 1 Jun 2023

Sanofi drug reduces disease activity in relapsing MS

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […]

June 1, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment of Neuraxpharm Netherlands, increasing its presences from two to 20 countries in six years. The company says the expansion into the Dutch market allows it to continue on its pathway to become the number one […]

December 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Jul 2022

First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association

Sandoz, a global pharmaceutical company working in generic and biosimilar medicines, announced this week that the US Food and Drug Administration (FDA) has accepted its biologics application (BLA) for treatment for people with multiple sclerosis (MS). The application is for a biosimilar natalizumab developed by Polpharma Biologics and includes all indications covered by the reference […]

July 28, 2022 - 3 minutesmins - By Liza Laws

geneuro multiple sclerosis neuron viral dna

News and Trends 18 Jul 2022

First-ever Marketing Authorization Application for biosimilar targeting MS filed

An international biotech, with headquarters in Amsterdam, has announced that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for its biosimilar product. Polpharma Biologics, which is dedicated to the development of biosimilars, announced on Friday (July 15) that natalizumab, similar to Tysabri, which treats multiple sclerosis, has been accepted as […]

July 18, 2022 - 3 minutesmins - By Liza Laws

multiple sclerosis novartis roche ema approval

News and Trends 27 Apr 2021

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […]

April 27, 2021 - 6 minutesmins - By Jonathan Smith

multiple sclerosis neuron sheath medday Pharma

News and Trends 11 Mar 2020

Phase III Fail for MedDay’s Multiple Sclerosis Treatment

A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms of multiple sclerosis in a phase III trial. The 642 patients recruited into the trial received either a placebo or a high dose of pharmaceutical-grade Biotin, also known as vitamin B₇. The patients had various forms of the autoimmune condition […]

March 11, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 17 Sep 2019

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis at a conference in Stockholm. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) gathered experts and companies working on multiple sclerosis in Sweden this year. Companies such as Genmab and GeNeuro revealed the progress of their treatments, […]

September 17, 2019 - 4 minutesmins - By Jonathan Smith

News and Trends 12 Mar 2019

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss biotech GeNeuro which carried out the research. GeNeuro’s monoclonal antibody drug targets the hidden viral protein because it’s linked to the occurrence of multiple sclerosis, […]

March 12, 2019 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Multiple sclerosis

The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval

Six biotech companies advancing multiple sclerosis therapies

10 neuroscience biotech companies you should know about

Are new treatments for multiple sclerosis on the horizon?

Sanofi drug reduces disease activity in relapsing MS

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association

First-ever Marketing Authorization Application for biosimilar targeting MS filed

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

Phase III Fail for MedDay’s Multiple Sclerosis Treatment

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!